DAMORA THERAPEUTICS, INC. Financing Cash Flow
DAMORA THERAPEUTICS, INC. (DMRA) reported Financing Cash Flow of $325.43 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Cash Flow › Financing Activities
us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2026-08-10
- DAMORA THERAPEUTICS, INC. net cash provided by (used in) financing activities for the quarter ending 2026-06-30 was $29.50M.
- DAMORA THERAPEUTICS, INC. net cash provided by (used in) financing activities for the quarter ending 2026-03-31 was $295.92M.
- DAMORA THERAPEUTICS, INC. net cash provided by (used in) financing activities for the quarter ending 2023-12-31 was $0.00, a 100.00% decline year-over-year.
- DAMORA THERAPEUTICS, INC. net cash provided by (used in) financing activities for the quarter ending 2023-09-30 was $171.00K, a 59.67% decline year-over-year.
- DAMORA THERAPEUTICS, INC. net cash provided by (used in) financing activities for fiscal 2025 was $266.84M.
- DAMORA THERAPEUTICS, INC. net cash provided by (used in) financing activities for fiscal 2023 was $2.88M, a 467.26% increase from fiscal 2022.
- DAMORA THERAPEUTICS, INC. net cash provided by (used in) financing activities for fiscal 2022 was $507.00K.
- DAMORA THERAPEUTICS, INC. net cash provided by (used in) financing activities for fiscal 2020 was $187.39M.
| Period end | Net Cash Provided by (Used in) Financing Activities 3 month | Net Cash Provided by (Used in) Financing Activities 6 month | Net Cash Provided by (Used in) Financing Activities 9 month | Net Cash Provided by (Used in) Financing Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $29.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | $325.43M 10-Q · filed 2026-08-10 | ||
| 2026-03-31 | $295.92M 10-Q · filed 2026-05-12 | |||
| 2025-12-31 | $266.84M 10-K · filed 2026-03-19 | |||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-19 | $171.00K derived: sum of 2 quarters · filed 2025-03-19 | $2.85M derived: sum of 3 quarters · filed 2025-03-19 | $2.88M 10-K · filed 2025-03-19 |
| 2023-09-30 | $171.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-01 | $2.85M derived: sum of 2 quarters · filed 2024-11-01 | $2.88M 10-Q · filed 2024-11-01 | $2.94M derived: sum of 4 quarters · filed 2024-11-01 |
| 2023-06-30 | $2.68M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | $2.71M 10-Q · filed 2024-08-12 | $2.77M derived: sum of 3 quarters · filed 2024-08-12 | $3.19M derived: sum of 4 quarters · filed 2024-08-12 |
| 2023-03-31 | $23.00K 10-Q · filed 2024-04-29 | $88.00K derived: sum of 2 quarters · filed 2024-04-29 | $512.00K derived: sum of 3 quarters · filed 2024-04-29 | |
| 2022-12-31 | $65.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-08 | $489.00K derived: sum of 2 quarters · filed 2024-03-08 | $507.00K 10-K · filed 2024-03-08 | |
| 2022-09-30 | $424.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-06 | $442.00K 10-Q · filed 2023-11-06 | ||
| 2022-06-30 | $18.00K 10-Q · filed 2023-07-31 | |||
| 2020-12-31 | $91.79M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-17 | $147.72M derived: sum of 2 quarters · filed 2022-02-17 | $147.72M derived: sum of 3 quarters · filed 2022-02-17 | $187.39M 10-K · filed 2022-02-17 |
| 2020-09-30 | $55.93M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | $55.93M derived: sum of 2 quarters · filed 2021-11-04 | $95.60M 10-Q · filed 2021-11-04 | |
| 2020-06-30 | $1.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | $39.67M 10-Q · filed 2021-08-05 | ||
| 2020-03-31 | $39.67M 10-Q · filed 2021-05-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Kardigan, Inc. (KARD) | United States | $1.346B |